KUKA

Phase A — Understand the business

Lens 1 · Company Overview

What it is. KUKA (from Keller und Knappich Augsburg) is a 127-year-old German industrial-automation company — founded 1898 in Augsburg by Johann Josef Keller and Jakob Knappich, originally an acetylene-lighting and welding-equipment maker. It built FAMULUS, one of the world's first electromechanical six-axis industrial robots, in 1973, and is today one of the "Big Four" global industrial-robot manufacturers alongside Fanuc, ABB and Yaskawa. It employs ~14,500 people and did ~€3.7–3.9B in revenue in 2024–25.

How it makes money — a diversified automation group, not a pure robot arm-maker. KUKA runs as five operating units:

• KUKA Robotics — the core: articulated industrial robots (the KR series, e.g. KR QUANTEC 90–300 kg payload, KR AGILUS small robots, the KR FORTEC/TITAN heavy line) and collaborative robots (the LBR iiwa / LBR "cobot", the world's first series-produced HRC-compatible sensitive robot). Sells robots + controllers + software, plus service/spares. ~€1.0B revenue in 2023.
• KUKA Systems — turnkey plant engineering and body-in-white assembly/welding lines, overwhelmingly for automotive OEMs. The larger unit by revenue (~€1.2B in 2023) but a lumpy, project-based, low-margin business.
• Swisslog — intralogistics / warehouse automation (AS/RS, AGVs, software). Diversifies KUKA away from auto into e-commerce/retail logistics.
• Swisslog Healthcare — hospital and pharmacy logistics automation (now folded into "Midea Medical," elevated to a Midea core business unit in April 2025 alongside "KUKA Medical" surgical robots).
• KUKA Digital (created 2025) — bundles software, AI and simulation (incl. the Visual Components sim platform and Device Insight IIoT unit) to sell "full digitalization of production systems." This is the strategic bet under the new CEO.

Customers / suppliers / competitors. Customers are heavily automotive — BMW, Volkswagen (>1,700 robots at Zwickau alone), Daimler/Mercedes, GM, Ford, Chrysler, Volvo, Hyundai — plus general industry, electronics, e-commerce logistics (Swisslog), and healthcare. Suppliers = motors, gearboxes/reducers (the harmonic-drive and RV-reducer chokepoint — see Lens 2), servo drives, controllers, and semiconductors. Competitors = Fanuc, ABB, Yaskawa (the other three of the Big Four) globally; Estun, Inovance, SIASUN, EFORT as fast-rising Chinese domestics. Contract structure: unit sales + large project contracts (Systems), no meaningful recurring/subscription revenue yet — this is capex-cyclical, order-book-driven, not ARR. Book-to-bill 1.09 in 2024.

The one fact that reframes everything: KUKA is a Chinese-owned German champion that "still does most of its product development in Germany" — an asset simultaneously excluded from parts of the Western defense/strategic market (via its Chinese parent — Lens 10) and losing its home Chinese market to domestic competitors its own parent is nurturing (Lens 3/13).

Lens 2 · Supply Chain

Map: upstream inputs → KUKA → end customer, named stakeholders.

• Upstream — the reducer chokepoint. The single most important input for an articulated robot is the precision gearbox/speed reducer (harmonic drives for wrist axes, RV/cycloidal reducers for the base). This market is a near-duopoly dominated by Japan's Harmonic Drive Systems (6324.T) and Nabtesco — a genuine single-vendor-class dependency for every Big-Four maker, KUKA included. Servo motors/drives, controllers, and application SoCs are the other key inputs. "ABB, KUKA, FANUC, and Yaskawa occupy approx. 60% of the Chinese [reducer-consuming] robot market". Note Fanuc and Yaskawa are vertically integrated into their own servos/controllers — a structural cost edge KUKA lacks.
• KUKA (own manufacturing). Robot assembly at Augsburg, Germany (HQ + primary plant) and — critically — at the Midea KUKA Intelligent Manufacturing Science & Technology Park in Shunde, Foshan (Guangdong, China), now "the largest industrial-robot production base in China" with >80,000 cumulative robots delivered. Midea has explicitly localized KUKA production into China.
• Downstream — the customer. Auto OEMs (body shops, EV battery/pack lines), Tier-1 suppliers, general manufacturing, e-commerce/retail warehouses (Swisslog), hospitals (Swisslog Healthcare). Sold direct and via a global system-integrator channel.
• The parent as supply-chain actor. Midea is not a passive owner — it is pulling KUKA into its own component ecosystem. The Midea humanoid-robot prototype reportedly has >80% self-made core components with "KUKA tech inside". Midea is using KUKA's motion-control IP to backward-integrate humanoids, and localizing KUKA's own supply base into China.

Chokepoints / single-source risks. (1) Precision reducers (Harmonic Drive / Nabtesco) — the industry-wide bottleneck; a cost and lead-time variable KUKA does not control. (2) Not being vertically integrated in servos/controllers vs. Fanuc/Yaskawa — a permanent BOM disadvantage. (3) Geopolitical: as a Chinese-owned entity, KUKA is exposed to both Western export controls on advanced compute and the risk of Western customers de-risking away from a Chinese-parented supplier. Named links: Harmonic Drive, Nabtesco, Midea, Shunde/Foshan park, BMW, VW — names present, lens passes.

Lens 3 · Competitive Advantages (moats)

What's actually defensible:

1. The Big-Four oligopoly + installed base. The top four (Fanuc/ABB/Yaskawa/KUKA) control ~75% of global industrial-robot shipments. That installed base creates switching costs: a factory tooled on KUKA controllers, KUKA.WorkVisual software, and KUKA service contracts does not re-platform cheaply. In premium automotive body-in-white welding, "precision robotics from ABB, KUKA and FANUC dominate" — this is a genuine high-reliability niche where the German brand still commands a premium.
2. Brand + German engineering reputation. In performance dimensions (repeatability, path accuracy, uptime), "foreign robot makers … generally outperform leading Chinese brands … across all of these performance dimensions". KUKA still sells on quality, not price.
3. Systems/integration know-how. Turnkey line-building for auto OEMs is a relationship-and-domain moat — hard for a component maker to replicate.

What is NOT a moat (the uncomfortable truth):

• The China home-market moat is gone. Chinese domestic makers went from 18% share (2015) → ~51% (2024); 52% of industrial robots sold in China in 2024 were domestic (up from 47% in 2023). Domestic products offer "competitive technical performance at prices 20–30% lower". KUKA's share of the Chinese market has slipped to ~9.5% and it is now out-ranked or matched by Estun (10%) and pressed by Inovance (8.2–8.8%) — companies that barely existed a decade ago.
• No vertical integration in servos/reducers vs. Fanuc/Yaskawa → structurally lower gross margin (Lens 7).
• Bargaining power is weakening on both sides: auto OEMs are consolidating robot spend and pushing price during the EV-capex air-pocket; upstream, the reducer duopoly holds pricing power over KUKA.

Net: a real but narrowing moat in premium/Western automotive robotics; a lost moat in its owner's home market. The moat is eroding, not compounding.

Lens 4 · Segments

No segments.csv on the shelf — all figures ``, and KUKA no longer breaks out clean public segment P&L post-delisting.

By division (revenue, most recent clean split available):

By geography (direction of travel, FY2024): declines in America and Europe; growth and record sales in Asia. The irony: Asia (largely China, via the Midea localization) is the growth region even as KUKA loses share there — volume up, share down, in a market growing faster than KUKA.

Trend & cause. Group revenue fell 7.9% to €3.7B in 2024 while orders rose 1.3% to €4.1B (book-to-bill 1.09) — i.e. billings decelerated on the EV-capex air-pocket and German/Chinese industrial malaise, but the order book grew, seeding a 2025 recovery. Order backlog ~€3.2B provides ~10 months of revenue cover. The deceleration is cyclical (EV-capex pause, macro), layered on a structural China-share loss — the dangerous combination.

---

Phase B — Measure performance

Lens 5 · Earnings Result

Latest clean full year — FY2024 (the "challenging year"): [all web: KUKA press release, 2025-04-25, unless noted]

• Sales revenue: €3.7B, −7.9% YoY (from €4.1B in 2023).
• Orders received: €4.1B, +1.3% YoY. Book-to-bill 1.09 (vs. 0.99 in 2023) — the leading indicator turned up.
• Order backlog: ~€3.2B.
• EBIT: €76.5M, −51.6% YoY (from €158.2M) — "due to the more competitive market and one-time effects from a major project." EBIT margin ~2.1% — thin for a Big-Four robot maker (peers run 20%+ operating margins on software/aftermarket — Lens 7).
• Net income: a €43.5M LOSS. This is the single most important number and it needs a flag: EBIT was positive (€76.5M) but the company printed a net loss — the ~€120M swing below the line points to interest expense (KUKA carries parent/external debt and EUR bonds), impairments/restructuring, and one-time project write-downs. See Lens 10.
• Free cash flow: a record €223.7M — driven by working-capital release, not earnings. FCF >> net income is a classic sign of a company harvesting working capital in a downturn (running down inventory/receivables) rather than growing.
• Market reaction: n/a — no live listing; the "reaction" was Midea forcing out the CEO (Lens 9).

Q1 2025 — the recovery signal: EBIT rose to €19.0M from €8.2M YoY, EBIT margin 2.2% vs 1.1%, on sales +18.3%. Orders, revenue and EBIT all up — consistent with the €3.2B backlog converting. FY2025 full-year figures are not cleanly sourced (third-party aggregators — Statista, Eulerpool, companiesmarketcap — give conflicting revenue of €3.38B–€3.9B and profit of ~€93–117M, all un-reconciled to KUKA's own report). Open item #1: reconcile FY2025 actuals to the KUKA Annual Report 2025. Do not treat the aggregator numbers as authoritative.

Unusual vs. own history: the EBIT halving, the swing to a net loss despite positive EBIT, and record FCF-on-falling-revenue are all atypical and all point the same way — a company defending cash while earnings compress under competitive + cyclical pressure.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts/ — KUKA holds no public earnings calls post-delisting (it reports to Midea, not to equity analysts). Sentiment is read off management commentary and the CEO transition. [all web]

• The tell is not a call — it's a defenestration. CEO Peter Mohnen (in the seat since 2018, prior 6 years as CFO) departed 1 July 2025 "at his own request," after 2024 operating results — "positive but below Midea's expectations" — and after Midea demanded more efficiency, higher profitability, and deeper cost cuts at the Augsburg site, which Mohnen resisted. Translation: the parent's patience with sub-scale German margins has run out.
• Tone shift: the language moved from Mohnen's 2021 "KUKA has achieved the turnaround" to a 2025 corporate framing of "focus on easier automation" and cost discipline. From growth story → efficiency story.
• What they stopped saying: independence, "German Mittelstand champion," standalone ambition. What they started saying: "Midea Medical," "full digitalization," "AI × robotics," localization into China.

Lens 7 · Comps

Peer set = the Big Four + the Chinese challenger + the parent. KUKA has no listed multiple (delisted) — so this table's job is to price what KUKA would be worth if it were still public, and to show how far below peer margins/multiples it sits. All market data ``; where I cannot source a figure it is n/a. No multiple is fabricated.

The comp read: KUKA operates at a ~2% EBIT margin vs. 15–26x-multiple peers earning 15–25% operating margins. If it re-listed, it would trade at a deep discount to Fanuc/ABB on both margin and growth — closer to a distressed-turnaround multiple than a premium-robotics one. The 2016 Midea offer of €115/share (a 36% premium) and the 2017 speculative peak of €297.88 were M&A-fever prices, not fundamentals; the €80.77 squeeze-out was the sober mark. On the parent: Midea at ~$91B is the only tradeable proxy, and robotics-and-automation (RMB 28.7B, −7.58% in 2024) is <8% of its RMB 409B revenue — KUKA is not a needle-mover for Midea holders.

Lens 8 · Stock-Price Catalysts

Pre-delisting history only; the tape ended 25 Nov 2022. All ``.

The 5-year "catalyst" history for KU2.DE is dominated by one variable: the Midea deal mechanics, not fundamentals:

• May 2016 — Midea's €115/share offer (+36% premium) sent the stock up and triggered a German/EU political firestorm over a strategic asset falling to China.
• Jan 2017 — deal closes at 94.55%; Oct 2017 — all-time peak €297.88 on takeover-completion speculation and robotics hype.
• 2018–2021 — long grind down as the standalone thesis faded, auto-capex softened, and Midea tightened control; Mohnen's "turnaround" claims propped sentiment.
• Nov 2021 → 2022 — Midea moves to full control (85.69% → squeeze-out), minorities out at €80.77, last trade 25 Nov 2022.

What the pattern reveals: for KUKA specifically, the market only ever truly reacted to ownership/control events and the strategic-asset geopolitics, not to quarterly execution — because from 2017 on it was a controlled subsidiary with a shrinking float. The lesson for the live thesis: there is no KUKA tape to trade; the relevant tape is Midea (000333.SZ) and the Big-Four robotics complex (Fanuc/ABB), where the catalysts that matter are auto-capex cycles, China robotics-share data, and humanoid-robot narrative.

---

Phase C — Judge people & books

Lens 9 · Management

• New CEO (from 1 July 2025): Christoph Schell, 53. Career at HP, Philips, and Intel — most recently Intel's Chief Commercial Officer / board member for Sales, Marketing & Communications (3D printing / digital manufacturing background). Sat on KUKA's Supervisory Board since 2023, chairing the Strategy & Technology Committee. Read: a commercial/computing/AI operator, not a lifer roboticist — installed to execute the "AI × robotics × digitalization" pivot and, per the subtext of Mohnen's exit, to deliver the cost cuts and margin Midea wants. A parent-aligned change agent.
• Departed CEO: Peter Mohnen — CEO 2018–2025, CFO before that; forced out over the Augsburg cost-cut/margin dispute with Midea. Skin-in-the-game / insider ownership is moot — there are no minority shares; Midea owns 100%.
• Capital allocation is Midea's, not KUKA's. Since 2017 the story is: Midea invested RMB 31.5B (€4B+ all-in) to acquire KUKA, localized production into the Shunde/Foshan park, folded healthcare into "Midea Medical" (2025), and is mining KUKA's motion-control IP for its own humanoids. From a Midea shareholder's lens this is a strategic-technology acquisition being sweated; from a KUKA-standalone lens it is an independent champion being absorbed and cost-managed.
• Red flags (governance): 100% parent ownership = related-party everything. Intercompany pricing, IP transfer to Midea's humanoid program, and the "Midea Medical" reorganization all happen without minority protection or independent-board scrutiny. The CEO change under parent pressure is itself the clearest governance signal — this is a subsidiary run for the parent's objectives.
• Archetype: professional-manager / conglomerate-subsidiary, decisively not founder-led. Implication: expect margin extraction, cost discipline, and IP contribution to the parent — not standalone empire-building.

Lens 10 · Forensic Red Flags

Web-only; no filings on the shelf. The starting point is Step-0's regulatory/regulatory-findings.md: KUKA has no CIK → zero SEC EDGAR (LR/AAER) findings possible. All below ``.

Accounting / quality-of-earnings flags (from the FY2024 figures):

1. Positive EBIT (€76.5M) but a net LOSS (€43.5M). The ~€120M below-the-line gap is the #1 forensic item. Sources attribute the EBIT drop itself to "one-time effects from a major project" — i.e. a loss-making Systems contract — but the further swing to a net loss implies material interest expense, impairments, and/or restructuring not visible in the press-release summary. This must be reconciled against the audited Annual Report 2024 (Open item #2).
2. Record FCF (€223.7M) massively exceeding a net loss. FCF this far above earnings in a down revenue year is a working-capital release (inventory/receivables run-down), which is not repeatable — it flatters cash while the P&L deteriorates. Watch for the reversal (working-capital rebuild) when orders convert in 2025.
3. Lumpy project accounting in KUKA Systems. Percentage-of-completion revenue recognition on large turnkey auto lines is inherently a soft spot — the "major project" one-time hit is exactly the kind of estimate-driven charge this business is prone to.
4. Related-party opacity (see Lens 9). As a 100%-Midea subsidiary, intercompany transactions, transfer pricing, and IP licensing to Midea's humanoid unit are not independently disclosed. For a bond investor this is the key monitoring risk; for an equity investor it is moot (you can't own it).

Regulatory / legal findings:

• SEC/EDGAR: none possible (no CIK) — verified via the Step-0 regulatory file.
• The material history is national-security, not accounting. During the 2016 takeover, CFIUS and the US DDTC scrutinized KUKA's US operations because a KUKA US subsidiary held ITAR-registered, defense-related work — including a contract with Northrop Grumman on fighter-jet manufacturing/maintenance. To clear the deal, Midea divested KUKA's North American division to Advanced Integration Technology (AIT). Germany's economics ministry cleared the deal (no compulsory review absent a direct military link), but the episode catalyzed Germany's and the EU's tightening of foreign-investment screening — the "clawback"/"be open but not stupid" policy shift.
• Ongoing: as a Chinese-owned supplier, KUKA faces latent risk of Western customer de-risking and export-control friction — a strategic-legal overhang, not a discrete enforcement action.
• Bottom line: No material accounting-fraud or SEC/AAER findings (none possible without a CIK; nothing surfaced on web). The real "red flag" is structural: a positive-EBIT/net-loss gap that needs audited reconciliation, plus a permanent geopolitical-ownership overhang.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

No EPS projection is meaningful — there is no share to earn EPS on. KUKA is delisted with no float; a per-share forecast would be fiction. This is exactly the "n/a / not applicable" discipline the skill demands, so I substitute an operating trajectory for the group and a read-through to Midea's automation segment. [all `` with inputs shown]

KUKA group operating path (revenue/EBIT, EUR):

• FY2024 actual: rev €3.7B, EBIT €76.5M (~2.1%), net −€43.5M.
• FY2025 base: rev ~€3.8–3.9B (Q1 sales +18.3%, backlog €3.2B converting), EBIT margin ~3–4% → EBIT ~€120–150M, back to a small net profit. Inputs: backlog conversion + Q1 run-rate annualized + Schell cost-cuts, partially offset by continued China-share loss and Systems lumpiness. Flag: aggregators cite FY2025 rev €3.38–3.9B / profit ~€93–117M — un-reconciled; treat as directional only (Open item #1).
• FY2026 base: rev ~€3.9–4.1B (industrial-robot market recovery — Interact Analysis sees shipments recovering in 2025 after a down 2024), EBIT margin ~4–5% as cost-outs land and mix shifts toward higher-margin Robotics/Digital vs. Systems. Bear: if China domestics keep taking share and EV-capex stays soft, revenue stalls at ~€3.6–3.7B and margin caps at ~3%. Bull: Digital/AI attach + Asia volume push margin toward mid-single-digits.

Read-through to the investable vehicle (Midea 000333.SZ): Midea's robotics-and-automation segment = RMB 28.7B, −7.58% in 2024, <8% of RMB 409B group revenue. A KUKA recovery to ~4% EBIT would add perhaps RMB ~1B of segment EBIT — immaterial to a ~$91B-cap parent doing RMB 38.5B net profit. For a Midea holder, KUKA is an optionality/technology line (humanoids, "Midea Medical"), not an earnings driver.

No forecast.ts Brier call logged — per --watchlist rules (skip the create step), and because there is no scoreable per-share number for a delisted entity. The trackable forecast, if promoted, would be on Midea's automation-segment revenue growth, not KUKA EPS.

Lens 12 · Bull vs Bear

Bull case (of the operating asset, for context — NOT an equity you can buy). KUKA is one of only four companies on earth with a full-stack, premium industrial-robot + turnkey-line + logistics-automation portfolio, ~€3.2B backlog, record FCF, and a book-to-bill back above 1.0. With Midea's balance sheet behind it, a China cost base, a credible new AI/commercial CEO (Schell), and a genuine humanoid-robotics optionality (KUKA motion-control IP inside Midea's prototype), it is positioned for a cyclical robotics recovery and a secular automation tailwind — a de-risked, deep-pocketed survivor of a brutal 2024.

Bear case (2–3 things that permanently impair it). (1) Structural China-share loss — domestics past 50% and taking premium tiers at −20-to-30% price; KUKA's home-market moat is already broken, and its owner is nurturing the competitors (Midea's own humanoid uses >80% self-made parts). (2) Permanent margin subscale — ~2% EBIT vs. Fanuc/ABB at 15–25%, with no servo/reducer vertical integration; the parent's answer is cost-cutting (which cost the last CEO his job), not a margin architecture. (3) Owned, not investable — the equity thesis is null; you cannot express a view except diluted ~1:12 through a $91B appliance conglomerate.

Pre-mortem (it's Jan 2028, "the thesis broke"). For a Midea holder: KUKA turned into a persistent low-return, capital-absorbing subsidiary; the humanoid narrative faded (Unitree/Chinese humanoids won on cost); the auto-robotics recovery undershot as EV-line buildout normalized; Western customers quietly de-sourced from a Chinese-owned supplier; and "Midea Medical"/Swisslog Healthcare underdelivered — leaving KUKA a ~2-4% margin, share-losing drag that the market ascribes ~zero value inside Midea.

Are multiples too high? For KUKA: no listed multiple exists. For Midea (~mid-teens P/E), the valuation is appliance-driven; robotics is neither in the price meaningfully nor a risk to it. The contrarian point: the market gives Midea essentially no credit for KUKA/robotics — which is arguably correct today, but is the cheap call option if humanoids or an auto-robotics super-cycle hit.

Contrarian view (what the market refuses to see). KUKA's real value to Midea isn't its ~2%-margin robot P&L — it's the motion-control / kinematics IP and the German engineering bench feeding Midea's humanoid ambitions. The consensus writes KUKA off as a struggling legacy robot maker; the non-obvious read is that Midea bought a humanoid-robotics capability in 2016 before "humanoid" was a word Wall Street cared about, and is now activating it. That optionality lives inside 000333.SZ, essentially unpriced.

Lens 13 · Devil's Advocate (short-seller)

If KUKA were listed, here is how I'd short it — and it doubles as the caution on Midea's robotics narrative.

• The moat is a melting ice cube in its own backyard. China is >40% of global robot demand, domestics own >50% and rising, they undercut on price 20–30%, and KUKA's China share (~9.5%) is below Estun's. A German-cost, Chinese-owned robot maker is squeezed from both ends — too expensive for cost-sensitive China, too Chinese-owned for security-sensitive West.
• Revenue concentration in the worst-timed end market. KUKA Systems (its biggest unit) is levered to automotive body-in-white — precisely the capex that boomed on the EV buildout and is now air-pocketing as EV line investment normalizes and Western auto slows. A single "major project" one-time hit halved 2024 EBIT — evidence of how lumpy and fragile the Systems earnings base is.
• The most dangerous competitor bulls underestimate is the parent. Midea is building humanoids with >80% self-made components; Chinese domestics (Unitree, Estun, Inovance) are climbing the quality curve fast. KUKA's technology lead is narrowing, not widening.
• Worst capital-allocation / governance: 100% parent ownership means every intercompany transaction and IP transfer to Midea's humanoid unit happens with zero minority protection — value can be routed to the parent. The CEO who resisted parent cost-cuts was removed.
• What must hold for any bull case: a robotics-capex recovery and margin expansion from ~2% to mid-single-digits and a halt to China-share loss and no Western de-risking. That's four things breaking right at once.
• −20-to-30% growth-disappointment scenario: revenue back to ~€3.4B with a Systems write-down flips KUKA back to a net loss and pure cash-preservation mode — the 2024 playbook, repeated.
• Single permanent-impairment scenario (most plausible): China domestics + Midea's own humanoid program relegate KUKA to a legacy Western-auto niche supplier, structurally low-growth, low-margin — worth a fraction of the €80.77 squeeze-out even before the ownership discount. Plausibility: moderate-to-high on a 3–5 year view.

Lens 14 · Management Questions (ordered by information value)

1. The €120M gap: EBIT was +€76.5M in 2024 but net income was −€43.5M — provide the full below-EBIT bridge (interest to Midea/external, impairments, restructuring, the "major project" charge). Is any of it recurring?
2. What is KUKA's China industrial-robot market share trajectory 2020→2025, and what is the concrete plan to stop the share loss to Estun/Inovance rather than just localize cost?
3. What EBIT margin can KUKA structurally reach, and by when — given no servo/reducer vertical integration vs. Fanuc/Yaskawa?
4. Quantify the intercompany IP arrangements with Midea's humanoid program: what KUKA technology is licensed/contributed, on what terms, and how is value attributed back to KUKA?
5. What proportion of revenue is automotive Systems vs. Robotics vs. Swisslog, and how do you de-risk the auto-capex cyclicality that halved 2024 EBIT?
6. Is the record FY2024 FCF (€223.7M) a repeatable structural improvement or a one-time working-capital release that reverses as orders convert?
7. What are the FY2025 audited revenue, EBIT and net income (to reconcile the conflicting third-party figures), and what is FY2026 guidance?
8. Post-Mohnen, what specific Augsburg cost actions is Schell executing, and what headcount/footprint change should we expect?
9. How exposed is KUKA to Western customer de-risking from a Chinese-owned supplier, and has it lost any defense-adjacent or strategic accounts since 2017?
10. What is the KUKA Digital revenue and margin ambition, and is software attach real recurring revenue or repackaged services?
11. How does "Midea Medical" (KUKA Medical surgical robots + Swisslog Healthcare) create value vs. dedicated med-robotics peers (Intuitive, Stryker)?
12. What is KUKA's exposure to the reducer duopoly (Harmonic Drive/Nabtesco) and any plan to internalize or dual-source it?
13. Are there any EUR bond covenants or parent guarantees that constrain KUKA's capital flexibility?
14. What would it take — financially and strategically — for Midea to ever re-IPO or partially float KUKA, and is that on the table?
15. Five years into full control, what is Midea's honest hold thesis for KUKA — margin harvest, humanoid IP engine, China champion, or eventual carve-out?

---